Streetbeat News

BAYRY

Bayer AG

https://www.bayer.de/

CEO

Werner Baumann

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

5.44

Mkt cap

22B

Volume

239K

High

5.51

P/E Ratio

-23.83

52-wk high

8.97

Low

5.44

Div yield

0.01

52-wk low

4.79

A survey by One A Day®, a Bayer brand, reveals that societal pressures significantly influence GenZ women's New Year's resolutions for 2025. Despite the trend of abandoning resolutions by mid-January, these women are determined to achieve their goals.

Portfolio Pulse from

January 17, 2025 | 4:00 pm

Bayer AG is advancing its pharmaceutical growth strategy with multiple regulatory filings for key drugs darolutamide, finerenone, and elinzanetant, as announced at the J.P. Morgan Healthcare Conference.

Portfolio Pulse from

January 14, 2025 | 6:45 pm

Bayer's pharmaceuticals division head announced that the company will focus on reducing debt and will not pursue major acquisitions in the next two to three years.

Portfolio Pulse from

January 14, 2025 | 7:45 am

Bayer announced that its investigational MRI contrast agent, gadoquatrane, met primary and secondary endpoints in Phase III studies, showing efficacy and safety at a reduced gadolinium dose.

Portfolio Pulse from

January 10, 2025 | 4:45 pm

Bayer is advancing its Radiology portfolio with innovations in AI and new collaboration agreements, which will be showcased at the RSNA 2024 meeting.

Portfolio Pulse from

December 01, 2024 | 3:30 pm

The FDA has accepted Bayer's supplemental New Drug Application (sNDA) for expanding the label of Nubeqa, a prostate cancer treatment. This marks a significant step in Bayer's efforts to broaden the use of Nubeqa.

Portfolio Pulse from

November 22, 2024 | 8:00 pm

Bayer shareholders urge CEO Bill Anderson to accelerate turnaround efforts to improve efficiency and drug development, aiming to restore confidence and revive the company's share price, which has hit 20-year lows.

Portfolio Pulse from

November 15, 2024 | 6:15 am

Bayer's third-quarter earnings were below expectations due to impairment losses in the Crop Science division. However, the Pharmaceutical business showed strong performance, with sales boosted by Nubeqa and Kerendia.

Portfolio Pulse from

November 12, 2024 | 8:00 pm

Bayer's stock faces risks from litigation and poor M&As, but its low valuation suggests potential long-term upside, especially post-2025. Despite challenges and a dividend cut, Bayer's fundamentals are solid, with a potential 30% annual upside. Consumer Health shows promise, but Crop Science and Pharma face headwinds.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

Bayer's stock is experiencing a significant decline, dropping 11% in German trading, following the company's announcement of a reduced full-year earnings target. The conglomerate also warned of potential lower profits next year due to challenges in the agricultural market.

Portfolio Pulse from

November 12, 2024 | 1:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.